Eupraxia Pharmaceuticals Reports EP-104GI Trial Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 21 2026
0mins
Should l Buy EPRX?
Eupraxia Pharmaceuticals announced 36-week tissue health and symptom data from patients in the highest dose cohort from its ongoing Phase 1b/2a part of the Resolve trial evaluating EP-104GI for the treatment of eosinophilic esophagitis, EoE. At 36 weeks, patients in Cohort 9 demonstrated a "robust" response in both tissue health and symptom response compared to their baseline levels. Patients in Cohort 9 also demonstrated the highest response in tissue health at week 36 compared to all other dose cohorts in the Resolve trial. Clinical remission in symptoms was maintained in 66% of the patients in Cohort 9 at week 36. This level of remission was first achieved at week 8 and was maintained through 36 weeks. EP-104GI continues to be well tolerated by patients receiving the drug; 31 patients have been treated in the Phase 1b/2a study and over 230 patient-months of follow-up have been reported with no drug related Serious Adverse Events. There still have been no cases of oropharyngeal candidiasis, a commonly reported adverse event with the oral delivery of steroids.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EPRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EPRX
Wall Street analysts forecast EPRX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.920
Low
11.02
Averages
13.02
High
16.03
Current: 6.920
Low
11.02
Averages
13.02
High
16.03
About EPRX
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eupraxia Pharmaceuticals Reports Q1 2026 Financial Results
- Widening Net Loss: Eupraxia Pharmaceuticals reported a net loss of $12.7 million for Q1 2026, up from $6.8 million in Q1 2025, primarily due to the doubling of the RESOLVE Part 2 trial size and increased administrative costs, despite a rise in other income, indicating ongoing investment in R&D amid financial pressures.
- Cash Position: As of March 31, 2026, the company had cash and cash equivalents of $58.5 million and short-term investments of $80.4 million, down from $80.6 million at the end of Q4 2025, reflecting the company's funding utilization during its R&D expansion.
- Funding Outlook: The company anticipates that its existing cash reserves and proceeds from the anticipated exercise of in-the-money warrants will be sufficient to fund operations into the second half of 2028, demonstrating confidence in future liquidity despite current losses.
- Share Structure: As of March 31, 2026, the company had 61,808,630 common shares and 8,355,638 preferred shares outstanding, indicating stability in its capital structure even while facing financial challenges.
See More
Eupraxia Appoints New Chief Medical Officer
- Executive Transition: Eupraxia Pharmaceuticals has appointed Dr. Jeymi Tambiah as Chief Medical Officer, succeeding the retiring Dr. Mark Kowalski, marking a significant leadership change aimed at advancing the company's gastroenterology pipeline during a critical clinical stage.
- Extensive Experience: Dr. Tambiah brings over 18 years of clinical development and regulatory experience from his tenure at Guys and St Thomas' Hospitals, and his expertise is expected to provide strategic advantages for Eupraxia's EP-104GI project, particularly in treating Eosinophilic Esophagitis.
- Clinical Trial Progress: Eupraxia's EP-104GI is currently undergoing a Phase 1b/2 RESOLVE clinical trial, utilizing a unique local injection method to deliver drugs directly into the esophageal wall, which is anticipated to offer new treatment options for patients.
- Technology Platform Potential: Eupraxia's Diffusphere™ technology aims to optimize localized drug delivery and may expand into oncology and infectious diseases, showcasing its broad application potential in areas with high unmet medical needs.
See More
Eupraxia Pharmaceuticals Reports Positive Phase 1b/2a Data for EP-104GI
- Clinical Trial Progress: Eupraxia Pharmaceuticals reported that in its ongoing Phase 1b/2a RESOLVE trial, EP-104GI demonstrated a reduction of 0.59 and 0.53 in EoEHSS Stage and Grade scores in the highest dose cohort at 36 weeks, reflecting significant improvements of 90% and 88%, indicating positive effects on both inflammatory and structural components of the disease.
- Eosinophil Count Reduction: At week 36, the peak eosinophil count fell by 72% from baseline, marking the largest reduction observed across all dose cohorts, showcasing the potential of EP-104GI in treating eosinophilic esophagitis.
- Good Safety Profile: Among the 31 patients treated, no drug-related serious adverse events were reported for EP-104GI, indicating a favorable tolerability profile that enhances its clinical applicability.
- Long-term Follow-up Data: With over 230 patient-months of follow-up data supporting the safety and efficacy of EP-104GI, this lays a strong foundation for future clinical applications and may enhance Eupraxia's competitive position in the eosinophilic esophagitis treatment market.
See More
Eupraxia Pharmaceuticals Reports Positive Phase 1b/2a Trial Data for Eosinophilic Esophagitis Treatment
- Clinical Trial Results: Eupraxia Pharmaceuticals reported that up to 76% of patients achieved remission in the Phase 1b/2a portion of its RESOLVE trial, with no serious safety concerns, indicating both efficacy and safety of the treatment.
- Remission Rate Analysis: The EP-104GI study revealed that 59% of patients achieved remission at 12 weeks, increasing to 76% at 24 weeks, alongside improvements in swallowing difficulty scores and key disease markers, showcasing the treatment's significant effectiveness.
- New Technology Application: A new cohort utilizing improved catheter delivery demonstrated significantly better outcomes, with the treatment well tolerated across all dose levels and no serious adverse events reported, further validating the safety of the treatment.
- Market Reaction: EPRX became a trending ticker on Stocktwits, reflecting investor interest in its positive clinical data, which may drive the company's future market performance and bolster investor confidence.
See More
Eupraxia Pharmaceuticals Reports Q4 Net Loss of $16.7 Million
- Widening Net Loss: Eupraxia Pharmaceuticals reported a net loss of $16.7 million for Q4 2025, compared to a net loss of $7.5 million in Q4 2024, indicating ongoing pressures in R&D and operations.
- Increased Cash Reserves: As of December 31, 2025, the company had cash reserves of $80.5 million, a significant increase from $33.1 million at the end of Q4 2024, reflecting positive developments in financing efforts.
- Optimistic Funding Outlook: The company anticipates that its existing cash reserves, along with proceeds from the offering and potential future exercise of in-the-money warrants, will be sufficient to fund operations into the second half of 2028, demonstrating confidence in future growth.
- Public Offering Plan: Eupraxia Pharmaceuticals has filed for a proposed public share offering aimed at further enhancing liquidity to support its R&D and market expansion strategies.
See More
Eupraxia Completes Public Offering of 7.6 Million Shares
- Successful Financing: Eupraxia Pharmaceuticals has successfully closed a public offering of 7.6 million common shares, raising approximately $63.2 million, which will significantly enhance its research capabilities for EP-104GI targeting eosinophilic esophagitis and facilitate the achievement of multiple development milestones.
- Clear Use of Proceeds: The company intends to allocate the funds primarily towards clinical trials for EP-104GI, including ongoing Phase 2 trials and preparations for a Phase 3 trial, thereby accelerating the product's market readiness to meet demand.
- Market Expansion Plans: Eupraxia will also use a portion of the proceeds to expedite clinical studies in additional gastrointestinal indications, such as esophageal strictures and fibrostenotic Crohn's disease, further broadening its product pipeline and enhancing market competitiveness.
- Strategic Investment: This fundraising not only supports the advancement of existing projects but also funds the development of new pipeline candidates and strengthens corporate infrastructure, ensuring sustainable growth and demonstrating the company's long-term commitment to the biotechnology sector.
See More
Eupraxia Pharmaceuticals Reports Q1 2026 Financial Results
- Widening Net Loss: Eupraxia Pharmaceuticals reported a net loss of $12.7 million for Q1 2026, up from $6.8 million in Q1 2025, primarily due to the doubling of the RESOLVE Part 2 trial size and increased administrative costs, despite a rise in other income, indicating ongoing investment in R&D amid financial pressures.
- Cash Position: As of March 31, 2026, the company had cash and cash equivalents of $58.5 million and short-term investments of $80.4 million, down from $80.6 million at the end of Q4 2025, reflecting the company's funding utilization during its R&D expansion.
- Funding Outlook: The company anticipates that its existing cash reserves and proceeds from the anticipated exercise of in-the-money warrants will be sufficient to fund operations into the second half of 2028, demonstrating confidence in future liquidity despite current losses.
- Share Structure: As of March 31, 2026, the company had 61,808,630 common shares and 8,355,638 preferred shares outstanding, indicating stability in its capital structure even while facing financial challenges.
See More
Eupraxia Appoints New Chief Medical Officer
- Executive Transition: Eupraxia Pharmaceuticals has appointed Dr. Jeymi Tambiah as Chief Medical Officer, succeeding the retiring Dr. Mark Kowalski, marking a significant leadership change aimed at advancing the company's gastroenterology pipeline during a critical clinical stage.
- Extensive Experience: Dr. Tambiah brings over 18 years of clinical development and regulatory experience from his tenure at Guys and St Thomas' Hospitals, and his expertise is expected to provide strategic advantages for Eupraxia's EP-104GI project, particularly in treating Eosinophilic Esophagitis.
- Clinical Trial Progress: Eupraxia's EP-104GI is currently undergoing a Phase 1b/2 RESOLVE clinical trial, utilizing a unique local injection method to deliver drugs directly into the esophageal wall, which is anticipated to offer new treatment options for patients.
- Technology Platform Potential: Eupraxia's Diffusphere™ technology aims to optimize localized drug delivery and may expand into oncology and infectious diseases, showcasing its broad application potential in areas with high unmet medical needs.
See More
Eupraxia Pharmaceuticals Reports Positive Phase 1b/2a Data for EP-104GI
- Clinical Trial Progress: Eupraxia Pharmaceuticals reported that in its ongoing Phase 1b/2a RESOLVE trial, EP-104GI demonstrated a reduction of 0.59 and 0.53 in EoEHSS Stage and Grade scores in the highest dose cohort at 36 weeks, reflecting significant improvements of 90% and 88%, indicating positive effects on both inflammatory and structural components of the disease.
- Eosinophil Count Reduction: At week 36, the peak eosinophil count fell by 72% from baseline, marking the largest reduction observed across all dose cohorts, showcasing the potential of EP-104GI in treating eosinophilic esophagitis.
- Good Safety Profile: Among the 31 patients treated, no drug-related serious adverse events were reported for EP-104GI, indicating a favorable tolerability profile that enhances its clinical applicability.
- Long-term Follow-up Data: With over 230 patient-months of follow-up data supporting the safety and efficacy of EP-104GI, this lays a strong foundation for future clinical applications and may enhance Eupraxia's competitive position in the eosinophilic esophagitis treatment market.
See More
Eupraxia Pharmaceuticals Reports Positive Phase 1b/2a Trial Data for Eosinophilic Esophagitis Treatment
- Clinical Trial Results: Eupraxia Pharmaceuticals reported that up to 76% of patients achieved remission in the Phase 1b/2a portion of its RESOLVE trial, with no serious safety concerns, indicating both efficacy and safety of the treatment.
- Remission Rate Analysis: The EP-104GI study revealed that 59% of patients achieved remission at 12 weeks, increasing to 76% at 24 weeks, alongside improvements in swallowing difficulty scores and key disease markers, showcasing the treatment's significant effectiveness.
- New Technology Application: A new cohort utilizing improved catheter delivery demonstrated significantly better outcomes, with the treatment well tolerated across all dose levels and no serious adverse events reported, further validating the safety of the treatment.
- Market Reaction: EPRX became a trending ticker on Stocktwits, reflecting investor interest in its positive clinical data, which may drive the company's future market performance and bolster investor confidence.
See More
Eupraxia Pharmaceuticals Reports Q4 Net Loss of $16.7 Million
- Widening Net Loss: Eupraxia Pharmaceuticals reported a net loss of $16.7 million for Q4 2025, compared to a net loss of $7.5 million in Q4 2024, indicating ongoing pressures in R&D and operations.
- Increased Cash Reserves: As of December 31, 2025, the company had cash reserves of $80.5 million, a significant increase from $33.1 million at the end of Q4 2024, reflecting positive developments in financing efforts.
- Optimistic Funding Outlook: The company anticipates that its existing cash reserves, along with proceeds from the offering and potential future exercise of in-the-money warrants, will be sufficient to fund operations into the second half of 2028, demonstrating confidence in future growth.
- Public Offering Plan: Eupraxia Pharmaceuticals has filed for a proposed public share offering aimed at further enhancing liquidity to support its R&D and market expansion strategies.
See More
Eupraxia Completes Public Offering of 7.6 Million Shares
- Successful Financing: Eupraxia Pharmaceuticals has successfully closed a public offering of 7.6 million common shares, raising approximately $63.2 million, which will significantly enhance its research capabilities for EP-104GI targeting eosinophilic esophagitis and facilitate the achievement of multiple development milestones.
- Clear Use of Proceeds: The company intends to allocate the funds primarily towards clinical trials for EP-104GI, including ongoing Phase 2 trials and preparations for a Phase 3 trial, thereby accelerating the product's market readiness to meet demand.
- Market Expansion Plans: Eupraxia will also use a portion of the proceeds to expedite clinical studies in additional gastrointestinal indications, such as esophageal strictures and fibrostenotic Crohn's disease, further broadening its product pipeline and enhancing market competitiveness.
- Strategic Investment: This fundraising not only supports the advancement of existing projects but also funds the development of new pipeline candidates and strengthens corporate infrastructure, ensuring sustainable growth and demonstrating the company's long-term commitment to the biotechnology sector.
See More
